Biomarkers in Rheumatoid Arthritis: From Traditional Serology to Precision Medicine Integration

TL;DR

This paper reviews new biomarkers for rheumatoid arthritis, highlighting which can help diagnose and manage the disease more precisely.

Contribution

The study evaluates emerging biomarkers in rheumatoid arthritis and identifies those with the strongest clinical potential.

Findings

14-3-3η protein and anti-carbamylated protein antibodies are validated for seronegative RA diagnosis and prognosis.

Calprotectin is useful for monitoring disease activity and treatment de-escalation decisions.

Multi-biomarker scores and imaging techniques like ultrasound and MRI show promise but require further validation.

Abstract

The biomarker landscape in rheumatoid arthritis (RA) is evolving from reliance on traditional markers toward integrated, multimodal strategies enabling precision medicine approaches. To critically evaluate emerging biomarkers across serological, cellular, genetic, imaging, and multi-omic domains, distinguishing those approaching clinical readiness from those requiring further development. In this study, a narrative review of the literature published between 2000 and 2024 relevant to clinical decision-making in RA was conducted. Among novel serological markers, 14-3-3η protein and anti-carbamylated protein antibodies show the strongest validation for seronegative disease and prognostic stratification. Calprotectin demonstrates utility for disease activity monitoring and de-escalation decisions. Multi-biomarker disease activity scores provide an objective assessment but lack outcome trial validation. Musculoskeletal ultrasound offers accessible imaging biomarker capability, while MRI bone marrow edema remains the strongest structural progression predictor. Synovial tissue pathotyping has demonstrated proof-of-concept for treatment stratification. Genetic, epigenetic, and metabolomic approaches remain investigational. Key clinical implications include using 14-3-3η and calprotectin to inform seronegative diagnosis and de-escalation decisions, integrating ultrasound for remission verification, and recognizing that emerging biomarkers for extra-articular complications, including cardiovascular risk and venous thromboembolism, represent important unmet needs.

Figures